Thus, PLZF is identified as an essential regulator of hepatic lipid and glucose metabolism, where the modulation of its liver expression could open up a therapeutic path for treating NAFLD. This evidence concerns the gene ZBTB16 and metabolic dysfunction-associated steatotic liver disease.